This single-center open-label nonrandomized, noncontrolled trial assesses the safety, tolerability, cerebrospinal fluid penetration, and biochemical changes associated with ambroxol therapy for the treatment of patients with Parkinson disease with and without mutations in the glucocerebrosidase gene. This evidence concerns the gene GBA1 and Parkinson disease.